Multimin Solution for Injection for Cattle

Composition

Each ml contains:

Active substances:

Zinc: 60 mg (equivalent to zinc oxide 74.68 mg)

Manganese: 10 mg (equivalent to manganese carbonate 20.92 mg)

Copper: 15 mg (equivalent to copper carbonate 26.09 mg)

Selenium: 5 mg (equivalent to sodium selenite 10.95 mg)

Excipients:

Clear blue solution.

3

Pharmacological properties

4.1 ATCvet code: QA12CX99

4.2 Pharmacodynamics

Manganese is indispensable for the action of glycotransferase. This enzyme plays a role in the formation of the mucopolysaccharide chondroitin sulphate, which is a component of cartilage and due to its action on the formation of cartilage, it is also important for bone formation. Mn is an important component of Mn superoxide dismutase enzyme used in the enzymatic antioxidant system.

Although manganese is also part of pyruvic carboxylase and several other enzymes, other divalent cations may serve as alternatives for its role in the activity of these enzymes.

Copper forms an integral part of a number of metalloproteins notably caeruloplasmin, monoamine oxidase, lysyl oxidase, cytochrome C and superoxide dismutase enzymes.

Zinc acts as a cofactor of numerous enzymes, e.g. alcohol dehydrogenase, carbonic anhydrase and carboxypeptidase. Zn is an important component of Zn superoxide dismutase enzyme used in the enzymatic antioxidant system. Zinc plays a role in protein synthesis and cell division. It also exerts crucial influence on the maintenance of cell membrane stability and in the function of the immune system. The connection between the known physiological functions of zinc and the various manifestations of zinc deficiency remain largely unexplained. Zinc interacts with several metabolic ions. Copper, calcium and phytate (a constituent of cereals) reduce zinc absorption; cadmium and zinc compete with each other.

Selenium exerts an antioxidative effect at the cell membrane against hydrogen peroxide and lipoperoxides. The effects are related to enzymatic activity of glutathione peroxidase (GSHPx) which contains selenocysteine. Selenium’s protective antioxidative action is partially linked to that of vitamin E. Selenocysteine is also an integral component of other functional proteins e.g. tetra- idothyronine-5-I-deiodinase (involved in metabolism of thyroid hormones) but the full extent of the biochemical mode of action of selenium in the body still remains to be elucidated.

4.3 Pharmacokinetics

Absorption:

• Following subcutaneous administration, the trace minerals are rapidly absorbed from the injection site.

Distribution:

• Once absorbed, manganese is transported to organs rich in mitochondria (in particular the liver, pancreas, and pituitary) where it is rapidly concentrated. The main organ involved in manganese accumulation is the liver which accumulates significantly higher levels of manganese statistically than the kidney. The turnover of manganese in mammalian tissues is rapid.

• Absorbed copper binds to plasma albumin and amino acids in the portal blood and is transported to the liver where it is incorporated into caeruloplasmin and later released into the plasma. Hepatic copper is distributed in several subcellular fractions associated with copper-dependent enzymes and copper-dependent proteins. Copper is also found in erythrocytes in the form of erythrocuprein and other proteins and in bone marrow bound to metallothionein.

• Zinc accumulation is most striking in muscle, followed by the liver, kidney and blood. Zinc values in muscle, liver and kidneys are similar.

• Parenteral selenium is initially transported by serum albumin, after absorption, and later by alpha-2 and beta-1globulin fractions. Selenium is distributed throughout the body, but the highest amounts are present in the liver, kidneys, and muscle.

Metabolism:

• Manganese does not metabolize; it is absorbed and excreted unchanged.

• Copper is available for metabolism by the liver when present as the form bound to albumin. The liver is the major storage organ for copper where it is protein bound, followed by the kidney, muscle and blood.

• After absorption into the body, zinc becomes bound to protein complexes, the most important of which is metallothionein, which acts as a carrier and transport mechanism. As an element zinc is not metabolized per se. Zinc does not accumulate in the body following continued [excessive] exposure.

• The metabolic process involving selenium is dependent on the chemical form and dose as well as on nutritional status. Major metabolites are methylated selenites. Two major metabolic products of selenite have been identified: dimethyl selenide and a trimethylselenonium ion.

Excretion:

• The liver, pancreas, adrenals and intestine play a role in the predominantly faecal excretion of manganese. Small amounts may be excreted in urine. For calves, 21% of an injected dose of manganese is excreted in bile.

• Excess copper is excreted mainly via bile and faeces, though urinary losses account for 0.5% to 3% of the daily intake.

• Excretion of absorbed zinc takes place mainly via bile (80%) and less so via urine and sweat.

3

Target species

Cattle.

3

Indications

Supply of trace minerals to correct concurrent clinical or subclinical deficiencies of selenium, copper, manganese and zinc which can arise during critical phases of the production or breeding life cycle.

3

Dosage

Strictly for subcutaneous use only.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Use standard aseptic procedures during administration of injections.

Strict adherence to correct subcutaneous injection technique should be employed.

Dosage:

Cattle - Up to 1 year: 1 ml per 50 kg

Cattle - From 1-2 years: 1 ml per 75 kg

Cattle - Over 2 years: 1 ml per 100 kg

Schedule of administration:

To be administered as a single administration during, or in advance of, periods of stress in the production and breeding life cycle likely to result in concurrent clinical or subclinical deficiencies of the four trace minerals (for example, transport/shipping, calving, breeding).

Maximal volume per injection site: 7 ml.

The 500 ml vial can be broached a maximum of 90 times.

3

Contraindications

Do not administer intramuscularly.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

3

Adverse reactions

Cattle:

Very common (>1 animal / 10 animals treated): Injection site swelling1, Injection site induration2

Common (1 to 10 animals / 100 animals treated): Injection site pain3

1 Moderate to severe that can persist for approximately 7 days following injection.

2 Estimated at less than 5 cm at palpation after 14 days following injection.

3 Mild. Immediate upon injection. Can persist for up to eight hours after injection.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3

Warnings

Special precautions for safe use in the target species:

Additional copper, zinc, manganese or selenium should not be administered at the same time.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product is HIGHLY concentrated in Selenium.

Due to a potential risk of Selenium toxicity, care should be taken when handling the veterinary medicinal product to avoid accidental self-injection.

The most common manifestations of accidental exposure to selenium in humans are gastrointestinal and neurological symptoms, such as nausea, vomiting, tenderness, fatigue and irritability.

When treating a large number of animals, a safe injection system should be used. Do not work alone when using the veterinary medicinal product.

Ensure that animals are properly restrained, including those in the vicinity. In case of accidental self-injection, SEEK MEDICAL ADVICE IMMEDIATELY and show the package leaflet or the label to the physician.

Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3

Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation.

3

Interactions

None known.

3

Overdose

No systemic adverse reactions were observed after repeated overdosing (3 consecutive daily administrations) at one to three times the recommended dose (i.e. 3x-9x recommended dose).

In one study, repeated overdosing (3 consecutive daily administrations) at 5.6x the recommended dose (i.e., 16.7x recommended dose) is associated with elevation of liver enzymes and hepatic centrilobular necrosis in six animals out of eight, with mortality in one animal.

3

Special warnings

None.

3

Withdrawal period

Meat and offal: 28 days.

Milk: zero hours.

3

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

3

Immediate packaging

Primary packaging: Clear Polyethylene Terephthalate (PET) vial closed with grey bromobutyl rubber stopper sealed with aluminium cap.

Package sizes:

Cardboard box containing one vial of 100 ml.

Cardboard box containing one vial of 500 ml.

Not all pack sizes may be marketed.

3

Storage

This veterinary medicinal product does not require any special storage conditions.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months. Shelf life after first opening the immediate packaging: 28 days.

3

Disposal of unused product

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

3

Additional information

Vm 42511/5000 Vm 42511/3000

8 DATE OF FIRST AUTHORISATION

14 July 2015

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

September 2025

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Approved 09 December 2025

3

Registration holder

Warburton Technology Limited

3